Kupfer G M, Näf D, D'Andrea A D
Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hematol Oncol Clin North Am. 1997 Dec;11(6):1045-60. doi: 10.1016/s0889-8588(05)70482-2.
Fanconi anemia (FA) is a rare, autosomal recessive disease characterized by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. Although traditionally described as a classic clinical syndrome, as more is discovered regarding its basic molecular and cell biology, FA is emerging as a true premalignant syndrome. Two of the genes of the five known complementation groups have been cloned, and work to understand their function is underway. Further understanding of these gene products has lent new ideas concerning modes of novel therapy, including gene therapy. The impact of molecular biology on our understanding of basic biology and the clinical care of FA patients is discussed.
范科尼贫血(FA)是一种罕见的常染色体隐性疾病,其特征为多种先天性异常、骨髓衰竭和癌症易感性。尽管传统上被描述为一种典型的临床综合征,但随着对其基础分子和细胞生物学的了解越来越多,FA正逐渐成为一种真正的癌前综合征。五个已知互补组中的两个基因已被克隆,对其功能的研究正在进行。对这些基因产物的进一步了解为包括基因治疗在内的新型治疗模式带来了新的思路。本文讨论了分子生物学对我们理解FA基础生物学及FA患者临床护理的影响。